Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: Long-term outcomes of a prospective study

Annals of Surgical Oncology

Volumn 16, Issue 12, 2009, Pages 3366-3374

  Langer, Igor ^a,b   Guller, Ulrich ^c   Viehl, Carsten T ^b   Moch, Holger ^d   Wight, Edward ^b   Harder, Felix ^b   Oertli, Daniel ^b   Zuber, Markus ^e  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Kantonsspital Olten ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROMETASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 71549116116     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0660-9     Document Type: Article

References (49)

1. AE Giuliano RC Jones M Brennan R Statman 1997 Sentinel lymphadenectomy in breast cancer J Clin Oncol 15 2345 2350 1:STN:280:DyaK2szjvFGmsg%3D%3D 9196149
2. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94:2542-51.
3. I Langer U Guller G Berclaz, et al. 2007 Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients Ann Surg 245 452 461 10.1097/01.sla.0000245472.47748.ec 17435553 (Pubitemid 46673142)
4. A Lucci LM McCall PD Beitsch, et al. 2007 Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011 J Clin Oncol 25 3657 3663 10.1200/JCO.2006.07.4062 17485711 (Pubitemid 47372604)
5. RE Mansel L Fallowfield M Kissin, et al. 2006 Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial J Natl Cancer Inst 98 599 609 16670385
6. KU Chu RR Turner NM Hansen MB Brennan AE Giuliano 1999 Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis Ann Surg Oncol 6 756 761 10.1007/s10434-999-0756-2 1:STN:280:DC%2BD3c%2Fos1aitw%3D%3D 10622503
7. G Viale E Maiorano G Pruneri, et al. 2005 Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy Ann Surg 241 319 325 10.1097/01.sla.0000150255.30665. 52 15650643
8. I Langer WR Marti U Guller, et al. 2005 Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy Ann Surg 241 152 158 15622003
9. I Langer M Zuber OR Kochli, et al. 2000 Validation study of the sentinel lymph node (SLN) method in invasive breast carcinoma. Personal data and review of the literature Swiss Surg 6 128 136 10.1024/1023-9332.6.3.128 1:STN:280:DC%2BD3cvlsFOrtw%3D%3D 10894014
10. A Goldhirsch JH Glick RD Gelber HJ Senn 1998 Meeting highlights: international consensus panel on the treatment of primary breast cancer J Natl Cancer Inst 90 1601 1608 10.1093/jnci/90.21.1601 1:STN:280: DyaK1M%2FislCnug%3D%3D 9811309
11. A Goldhirsch JH Glick RD Gelber AS Coates HJ Senn 2001 Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer J Clin Oncol 19 3817 3827 1:STN:280:DC%2BD3Mrht1Slsw%3D%3D 11559719
12. U Veronesi V Galimberti L Mariani, et al. 2005 Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection Eur J Cancer 41 231 237 10.1016/j.ejca.2004.05.009 15661547 (Pubitemid 40126955)
13. AE Giuliano PI Haigh MB Brennan, et al. 2000 Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer J Clin Oncol 18 2553 2559 1:STN:280:DC%2BD3czlt1Snug%3D%3D 10893286
14. DN Krag SJ Anderson TB Julian, et al. 2007 Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial Lancet Oncol 8 881 888 10.1016/S1470-2045(07) 70278-4 1:CAS:528:DC%2BD2sXhtFektbzM 17851130 (Pubitemid 47488052)
15. RC Martin A Chagpar CR Scoggins, et al. 2005 Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer Ann Surg 241 1005 1012 10.1097/01.sla.0000165200.32722.02 15912050 (Pubitemid 40733976)
16. L Bergkvist J Frisell 2005 Multicentre validation study of sentinel node biopsy for staging in breast cancer Br J Surg 92 1221 1224 10.1002/bjs.5052 1:STN:280:DC%2BD2MrhsFeltA%3D%3D 15988791 (Pubitemid 41475230)
17. U Veronesi G Paganelli G Viale, et al. 2003 A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer N Engl J Med 349 546 553 10.1056/NEJMoa012782 12904519 (Pubitemid 36951366)
18. S Shivers C Cox G Leight, et al. 2002 Final results of the Department of Defense multicenter breast lymphatic mapping trial Ann Surg Oncol 9 248 255 10.1007/BF02573062 11923131
19. L Tafra DR Lannin MS Swanson, et al. 2001 Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye Ann Surg 233 51 59 10.1097/00000658-200101000-00009 1:STN:280:DC%2BD3M3pvFCrsg%3D%3D 11141225 (Pubitemid 32042775)
20. HS Cody III AD Hill KN Tran MF Brennan PI Borgen 1999 Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg 229 723 726 10.1097/00000658-199905000-00015 10235531 (Pubitemid 30187580)
21. IM van der Ploeg OE Nieweg MC van Rijk RA Valdés Olmos BB Kroon 2008 Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature Eur J Surg Oncol 34 1277 1284 1:STN:280:DC%2BD1cjhsFCruw%3D%3D 18406100
22. M Al Hajj MS Wicha A Benito-Hernandez SJ Morrison MF Clarke 2003 Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 3983 3988 10.1073/pnas.0530291100 1:CAS:528:DC%2BD3sXivFSqtbs%3D 12629218 (Pubitemid 36418143)
23. C Colpaert P Vermeulen W Jeuris, et al. 2001 Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour J Pathol 193 442 449 10.1002/path.829 1:STN:280:DC%2BD3M7oslaktg%3D%3D 11276002 (Pubitemid 32266812)
24. T Furukawa T Kubota H Tanino, et al. 2000 Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay Anticancer Res 20 3657 3658 1:CAS:528:DC%2BD3cXovVKisLs%3D 11268434
25. AD Hill KN Tran T Akhurst, et al. 1999 Lessons learned from 500 cases of lymphatic mapping for breast cancer Ann Surg 229 528 535 10.1097/00000658- 199904000-00012 1:STN:280:DyaK1M3hslOgtA%3D%3D 10203086 (Pubitemid 30191751)
26. C Reynolds R Mick JH Donohue, et al. 1999 Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 17 1720 1726 1:STN:280:DC%2BD3c%2FivF2gtQ%3D%3D 10561208
27. RR Turner KU Chu K Qi, et al. 2000 Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node Cancer 89 574 581 10.1002/1097-0142(20000801)89: 3<574::AID-CNCR12>3.0.CO;2-Y 1:STN:280:DC%2BD3cvgt1arsA%3D%3D 10931456 (Pubitemid 30640103)
28. U Veronesi G Paganelli G Viale, et al. 1999 Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series J Natl Cancer Inst 91 368 373 10.1093/jnci/91.4.368 1:STN:280:DyaK1M7lvVWmug%3D%3D 10050871
29. U Veronesi V Galimberti S Zurrida, et al. 2001 Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer Eur J Cancer 37 454 458 10.1016/S0959-8049(00)00410-X 1:STN:280:DC%2BD3M7mvFOisA%3D%3D 11267853 (Pubitemid 32232108)
30. DL Weaver DN Krag T Ashikaga SP Harlow M O'Connell 2000 Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study Cancer 88 1099 1107 10.1002/(SICI)1097-0142(20000301)88: 5<1099::AID-CNCR22>3.0.CO;2-7 1:STN:280:DC%2BD3c7msVemug%3D%3D 10699901 (Pubitemid 30127672)
31. PR Rosen S Groshen PE Saigo DW Kinne S Hellman 1989 A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma J Clin Oncol 7 355 366 1:STN:280:DyaL1M7ktV2htg%3D%3D 2918331
32. K Dowlatshahi M Fan HC Snider FA Habib 1997 Lymph node micrometastases from breast carcinoma: reviewing the dilemma Cancer 80 1188 1197 10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H 1:STN:280:DyaK2svmtFCrug%3D%3D 9317169 (Pubitemid 27407219)
33. RJ Cote HF Peterson B Chaiwun, et al. 1999 Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group Lancet 354 896 900 10.1016/S0140-6736(98)11104-2 1:STN:280:DyaK1MvhvVCrsg%3D%3D 10489948 (Pubitemid 29424019)
34. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet. 1990;335:1565-8.
35. M Colleoni N Rotmensz G Peruzzotti, et al. 2005 Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement J Clin Oncol 23 1379 1389 10.1200/JCO.2005.07.094 15735114 (Pubitemid 46260025)
36. U Veronesi G Paganelli G Viale, et al. 2006 Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study Lancet Oncol 7 983 990 10.1016/S1470-2045(06)70947-0 17138219 (Pubitemid 44804136)
37. A Chagpar LP Middleton AA Sahin, et al. 2005 Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry Cancer 103 1581 1586 10.1002/cncr.20934 15747375 (Pubitemid 40490018)
38. A Ganaraj JA Kuhn RC Jones, et al. 2003 Predictors for nonsentinel node involvement in breast cancer patients with micrometastases in the sentinel lymph node Proc (Bayl Univ Med Cent) 16 3 6
39. WC Liang BJ Sickle-Santanello TA Nims 2001 Is a completion axillary dissection indicated for micrometastases in the sentinel lymph node? Am J Surg 182 365 368 10.1016/S0002-9610(01)00738-3 1:STN:280:DC%2BD3MnnsVOiug%3D%3D 11720672 (Pubitemid 33079088)
40. K Fournier A Schiller RR Perry C Laronga 2004 Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection Ann Surg 239 859 863 10.1097/01.sla.0000128302.05898.a7 15166965 (Pubitemid 38669436)
41. P Schrenk P Konstantiniuk S Wolfl, et al. 2005 Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node Br J Surg 92 707 713 10.1002/bjs.4937 1:STN:280:DC%2BD2M3otVehtg%3D%3D 15810047 (Pubitemid 40863189)
42. JM Guenther NM Hansen LA DiFronzo, et al. 2003 Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes Arch Surg 138 52 56 12511150
43. JS Fant MD Grant SM Knox, et al. 2003 Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection Ann Surg Oncol 10 126 130 10.1245/ASO.2003.04.022 12620906 (Pubitemid 40485931)
44. JS Jeruss DJ Winchester SF Sener, et al. 2005 Axillary recurrence after sentinel node biopsy Ann Surg Oncol 12 34 40 10.1007/s10434-004-1164-2 15827776 (Pubitemid 40486639)
45. AM Naik J Fey M Gemignani, et al. 2004 The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures Ann Surg 240 462 468 10.1097/01.sla.0000137130.23530.19 15319717 (Pubitemid 39121340)
46. YG Fan YY Tan CT Wu, et al. 2005 The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer Ann Surg Oncol 12 705 711 10.1245/ASO.2005.08.020 16079953 (Pubitemid 41206916)
47. JT Carlo MD Grant SM Knox, et al. 2005 Survival analysis following sentinel lymph node biopsy: a validation trial demonstrating its accuracy in staging early breast cancer Proc (Bayl Univ Med Cent) 18 103 107
48. A Haid M Knauer R Koeberle-Wuehrer, et al. 2006 Medium-term follow-up data after sentinel node biopsy alone for breast cancer Eur J Surg Oncol 32 1180 1185 10.1016/j.ejso.2006.04.010 1:STN:280:DC%2BD28novVektA%3D%3D 16750344 (Pubitemid 44793674)
49. RF Hwang AM Gonzalez-Angulo TA Buchholz, et al. 2007 Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection Cancer 110 723 730 10.1002/cncr.22847 17587208 (Pubitemid 47257646)